0.7267
price down icon3.11%   -0.0233
pre-market  プレマーケット:  .73   0.0033   +0.45%
loading
前日終値:
$0.75
開ける:
$0.7492
24時間の取引高:
3.33M
Relative Volume:
0.91
時価総額:
$104.84M
収益:
$400.57M
当期純損益:
$9.21M
株価収益率:
18.17
EPS:
0.04
ネットキャッシュフロー:
$146.36M
1週間 パフォーマンス:
-28.05%
1か月 パフォーマンス:
-52.81%
6か月 パフォーマンス:
-83.63%
1年 パフォーマンス:
-90.50%
1日の値動き範囲:
Value
$0.7002
$0.7801
1週間の範囲:
Value
$0.591
$1.02
52週間の値動き範囲:
Value
$0.591
$8.45

Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile

Name
名前
Ironwood Pharmaceuticals Inc
Name
セクター
Healthcare (1151)
Name
電話
617-621-7722
Name
住所
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Name
職員
253
Name
Twitter
@ironwoodpharma
Name
次回の収益日
2025-02-21
Name
最新のSEC提出書
Name
IRWD's Discussions on Twitter

IRWD を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - Specialty & Generic icon
IRWD
Ironwood Pharmaceuticals Inc
0.7267 104.84M 400.57M 9.21M 146.36M 0.04
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
148.67 67.28B 9.26B 2.49B 2.30B 5.47
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.22 45.62B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.71 45.01B 30.25B 1.37B 5.08B 0.4257
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
13.65 15.60B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
284.73 12.77B 2.76B 1.11B 898.10M 22.77

Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-04-15 ダウングレード Jefferies Buy → Hold
2025-04-15 ダウングレード Wells Fargo Overweight → Equal Weight
2025-04-14 ダウングレード Citizens JMP Mkt Outperform → Mkt Perform
2024-09-09 開始されました Leerink Partners Market Perform
2024-08-08 ダウングレード CapitalOne Overweight → Equal Weight
2024-01-17 開始されました Craig Hallum Buy
2023-12-14 開始されました Wells Fargo Overweight
2023-11-09 開始されました Jefferies Buy
2023-09-28 開始されました JMP Securities Mkt Outperform
2022-09-02 開始されました CapitalOne Overweight
2022-04-22 開始されました Piper Sandler Overweight
2020-09-30 ダウングレード Wells Fargo Overweight → Equal Weight
2020-06-17 開始されました Northland Capital Outperform
2019-07-10 再開されました Credit Suisse Neutral
2019-03-27 アップグレード Morgan Stanley Underweight → Equal-Weight
2019-02-25 アップグレード H.C. Wainwright Sell → Neutral
2019-01-24 アップグレード JP Morgan Underweight → Neutral
2018-11-07 ダウングレード Credit Suisse Outperform → Neutral
2018-11-07 ダウングレード JP Morgan Neutral → Underweight
2018-07-23 開始されました H.C. Wainwright Sell
2018-05-09 ダウングレード Morgan Stanley Equal-Weight → Underweight
2018-01-05 ダウングレード BofA/Merrill Buy → Underperform
2017-12-06 ダウングレード Mizuho Buy → Neutral
2017-07-21 ダウングレード JP Morgan Overweight → Neutral
2017-05-03 開始されました Wells Fargo Outperform
2017-04-07 繰り返されました Mizuho Buy
2017-02-22 繰り返されました Barclays Equal Weight
2016-11-04 繰り返されました Mizuho Buy
2016-10-24 繰り返されました Wedbush Neutral
2016-10-10 繰り返されました Mizuho Buy
2016-09-27 繰り返されました WallachBeth Hold
すべてを表示

Ironwood Pharmaceuticals Inc (IRWD) 最新ニュース

pulisher
Apr 18, 2025

Ironwood looks for strategic options after regulatory hurdle for lead drug - MSN

Apr 18, 2025
pulisher
Apr 17, 2025

Why Ironwood Pharmaceuticals Inc. (IRWD) Went Down On Thursday? - MSN

Apr 17, 2025
pulisher
Apr 16, 2025

Ironwood Shares Tank on Regulatory Update for Apraglutide - MSN

Apr 16, 2025
pulisher
Apr 16, 2025

Ironwood Pharmaceuticals (IRWD) Faces Setback After FDA Request - GuruFocus

Apr 16, 2025
pulisher
Apr 16, 2025

Ironwood Pharmaceuticals (IRWD) Faces Downgrade and Challenges A - GuruFocus

Apr 16, 2025
pulisher
Apr 15, 2025

Ironwood downgraded at Jefferies on apraglutide-related challenges - MSN

Apr 15, 2025
pulisher
Apr 15, 2025

Jefferies Downgrades Ironwood Pharmaceuticals (IRWD) - MSN

Apr 15, 2025
pulisher
Apr 15, 2025

Wells Fargo Downgrades Ironwood Pharmaceuticals (IRWD) - MSN

Apr 15, 2025
pulisher
Apr 15, 2025

Ironwood downgraded at Jefferies on apraglutide-related challenges (IRWD:NASDAQ) - Seeking Alpha

Apr 15, 2025
pulisher
Apr 15, 2025

This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

Wells Fargo Downgrades Ironwood Pharmaceuticals to Equalweight From Overweight, Adjusts Price Target to $1 From $7 - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

Jefferies Downgrades Ironwood Pharmaceuticals to Hold From Buy, Adjusts Price Target to $0.70 From $8 - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

Ironwood crashes down as FDA seeks new phase 3 trial - Pharmaphorum

Apr 15, 2025
pulisher
Apr 15, 2025

Ironwood (IRWD) Shares Downgraded by Jefferies Following FDA Set - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide | IRWD Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 14, 2025

Ironwood (IRWD) Plummets After Downgrade and FDA Trial Delay | I - GuruFocus

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood To Consider All Options With Apraglutide Setback In SBS - insights.citeline.com

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood's Strategy Shake-Up Raises Eyebrows As Shares Tumble - Finimize

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood requires new trial for SBS drug approval By Investing.com - Investing.com South Africa

Apr 14, 2025
pulisher
Apr 14, 2025

Top Midday Decliners - MarketScreener

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug - Benzinga

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood to considers merger opportunities after FDA setback - The Business Journals

Apr 14, 2025
pulisher
Apr 14, 2025

Crude Oil Moves Lower; M&T Bank Earnings Miss Views - Benzinga

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood (IRWD) Faces Financial Uncertainty as Price Target is S - GuruFocus

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood (IRWD) Faces Financial Uncertainty as Price Target is Slashed | IRWD Stock News - GuruFocus

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood: FDA nay on PK means another apraglutide study - BioWorld MedTech

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide - BioSpace

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood Pharmaceuticals (IRWD) Considers Strategic Options Afte - GuruFocus

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood Pharmaceuticals stock tumbles after FDA requires additional trial By Investing.com - Investing.com India

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood Pharmaceuticals stock tumbles after FDA requires additional trial - Investing.com Australia

Apr 14, 2025
pulisher
Apr 14, 2025

Nasdaq Surges 2%; Goldman Sachs Posts Upbeat Earnings - Benzinga

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood Says FDA to Require Additional Phase 3 Trial for Apraglutide; to Explore Strategic Options - MarketScreener

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood Pharma stock down on regulatory hurdle (IRWD:NASDAQ) - Seeking Alpha

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood Pharma Provides Update On Apraglutide; Plans Strategic Alternatives - Nasdaq

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood (IRWD) Plans New Phase 3 Trial for Apraglutide Followin - GuruFocus

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood (IRWD) Plans New Phase 3 Trial for Apraglutide Following FDA Talks | IRWD Stock News - GuruFocus

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood Pharmaceuticals to Explore Strategic Alternatives to Maximize Value for Stockholders - marketscreener.com

Apr 14, 2025
pulisher
Apr 10, 2025

Ironwood Pharmaceuticals: Setting A Strong Foundation For A Return To Growth - Seeking Alpha

Apr 10, 2025
pulisher
Apr 08, 2025

Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) Stock Sentiment: What’s Wall Street Saying? - stocksregister.com

Apr 08, 2025
pulisher
Mar 31, 2025

Short Bowel Syndrome Market Growth Projections 2024-2034: - openPR.com

Mar 31, 2025
pulisher
Mar 31, 2025

IRONWOOD PHARMACEUTICALS INC SEC 10-K Report - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Ironwood Pharmaceuticals Inc. (IRWD) reports earnings - qz.com

Mar 31, 2025
pulisher
Mar 27, 2025

Ironwood Pharmaceuticals (IRWD) Faces Nasdaq Compliance Deadline - GuruFocus

Mar 27, 2025
pulisher
Mar 27, 2025

Ironwood Pharmaceuticals Gets Nasdaq Non-Compliance Notice - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing - Business Wire

Mar 27, 2025
pulisher
Mar 25, 2025

Catalyst (CPRX) Surges 6.2%: Is This an Indication of Further Gains? - Yahoo Finance

Mar 25, 2025
pulisher
Mar 23, 2025

Charles Schwab Investment Management Inc. Has $8.79 Million Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Defense World

Mar 23, 2025
pulisher
Mar 21, 2025

Irritable Bowel Syndrome Treatment Market Future Business - openPR.com

Mar 21, 2025
pulisher
Mar 21, 2025

StockNews.com Downgrades Ironwood Pharmaceuticals (NASDAQ:IRWD) to Hold - Armenian Reporter

Mar 21, 2025
pulisher
Mar 20, 2025

Ironwood Pharmaceuticals Inc (NASDAQ: IRWD): Blank Check On Growth? - Stocks Register

Mar 20, 2025
pulisher
Mar 20, 2025

Analysts Set Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Price Target at $8.60 - Defense World

Mar 20, 2025

Ironwood Pharmaceuticals Inc (IRWD) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Ironwood Pharmaceuticals Inc (IRWD) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Silver Ronald
Principal Accounting Officer
Feb 10 '25
Sale
1.76
12,048
21,204
279,655
Shetzline Michael
SVP, CMO, Head-Res&Drug
Feb 10 '25
Sale
1.76
41,269
72,633
554,007
John Minardo
Chief Legal Officer
Feb 10 '25
Sale
1.76
38,938
68,531
408,132
Martini Gregory S.
Chief Financial Officer
Feb 10 '25
Sale
1.76
12,052
21,212
183,810
$27.00
price down icon 0.74%
$101.32
price up icon 0.80%
$7.56
price up icon 2.30%
$101.38
price up icon 1.28%
drug_manufacturers_specialty_generic RDY
$13.67
price up icon 1.71%
$284.73
price down icon 0.16%
大文字化:     |  ボリューム (24 時間):